VICI Properties Inc vs GeneDx Holdings Corp — how do they compare? VICI Properties Inc trades at $22.87 (market cap $25.09B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: VICI Properties Inc is far larger — about 12.4× GeneDx Holdings Corp's market cap, and VICI Properties Inc pays a 8.07% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold VICI Properties Inc for 42 Days and GeneDx Holdings Corp for 19 Days on average.
| VICI | WGS | |
|---|---|---|
Market Cap | $25.09B | $2.02B |
Volume | 17,066,337 | 734,640 |
Sector | Real Estate | Health |
52-Week High | $31.42 | $167.51 |
52-Week Low | $22.53 | $34.51 |
Typical Hold Time | 42 Days | 19 Days |
Enterprise Value | $42.65B | $2.05B |
Dividend Yield | 8.07% | — |
Signals from Pluang's Aura AI — not financial advice
VICI Properties trades at $22.64, down 0.4% on the day, with a bearish technical outlook despite strong fundamentals. The REIT maintains exceptional profitability with 67.5% net margins and trades at attractive valuations (P/E 8.83, P/B 0.86). Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing, while the company continues expanding its tenant base through new lease agreements.
Wall Street remains bullish with 75% buy ratings and a $28.90 consensus target, representing 28% upside. Key risks include tenant concentration and rising interest rates, but the 7.8% dividend yield appears well-covered by strong cash flows. The current discount to NAV presents a compelling opportunity for income-focused investors.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →